55 related articles for article (PubMed ID: 31446228)
1. An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.
Morgensztern D; Karaseva N; Felip E; Delgado I; Burdaeva O; Dómine M; Lara P; Paik PK; Lassen U; Orlov S; Trigo J; Shomova M; Baker-Neblett K; Vasquez J; Wang X; Yan L; Mitrica I; DeYoung MP; Garrido P
Lung Cancer; 2019 Oct; 136():74-79. PubMed ID: 31446228
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
Dy GK; Mandrekar SJ; Nelson GD; Meyers JP; Adjei AA; Ross HJ; Ansari RH; Lyss AP; Stella PJ; Schild SE; Molina JR; Adjei AA
J Thorac Oncol; 2013 Jan; 8(1):79-88. PubMed ID: 23232491
[TBL] [Abstract][Full Text] [Related]
3. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
Doebele RC; Conkling P; Traynor AM; Otterson GA; Zhao Y; Wind S; Stopfer P; Kaiser R; Camidge DR
Ann Oncol; 2012 Aug; 23(8):2094-2102. PubMed ID: 22345119
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
Nogova L; Sequist LV; Perez Garcia JM; Andre F; Delord JP; Hidalgo M; Schellens JH; Cassier PA; Camidge DR; Schuler M; Vaishampayan U; Burris H; Tian GG; Campone M; Wainberg ZA; Lim WT; LoRusso P; Shapiro GI; Parker K; Chen X; Choudhury S; Ringeisen F; Graus-Porta D; Porter D; Isaacs R; Buettner R; Wolf J
J Clin Oncol; 2017 Jan; 35(2):157-165. PubMed ID: 27870574
[TBL] [Abstract][Full Text] [Related]
5. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
Vergote I; Van Nieuwenhuysen E; O'Cearbhaill RE; Westermann A; Lorusso D; Ghamande S; Collins DC; Banerjee S; Mathews CA; Gennigens C; Cibula D; Tewari KS; Madsen K; Köse F; Jackson AL; Boere IA; Scambia G; Randall LM; Sadozye A; Baurain JF; Gort E; Zikán M; Denys HG; Ottevanger N; Forget F; Mondrup Andreassen C; Eaton L; Chisamore MJ; Viana Nicacio L; Soumaoro I; Monk BJ
J Clin Oncol; 2023 Dec; 41(36):5536-5549. PubMed ID: 37651655
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer.
Cihoric N; Savic S; Schneider S; Ackermann I; Bichsel-Naef M; Schmid RA; Lardinois D; Gugger M; Bubendorf L; Zlobec I; Tapia C
Br J Cancer; 2014 Jun; 110(12):2914-22. PubMed ID: 24853178
[TBL] [Abstract][Full Text] [Related]
7. An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy.
Yamamoto N; Kenmotsu H; Goto K; Takeda K; Kato T; Takeda M; Horinouchi H; Saito I; Sarashina A; Tanaka T; Morsli N; Nakagawa K
Cancer Chemother Pharmacol; 2018 Oct; 82(4):685-694. PubMed ID: 30073583
[TBL] [Abstract][Full Text] [Related]
8. Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.
Malchers F; Nogova L; van Attekum MH; Maas L; Brägelmann J; Bartenhagen C; Girard L; Bosco G; Dahmen I; Michels S; Weeden CE; Scheel AH; Meder L; Golfmann K; Schuldt P; Siemanowski J; Rehker J; Merkelbach-Bruse S; Menon R; Gautschi O; Heuckmann JM; Brambilla E; Asselin-Labat ML; Persigehl T; Minna JD; Walczak H; Ullrich RT; Fischer M; Reinhardt HC; Wolf J; Büttner R; Peifer M; George J; Thomas RK
J Clin Invest; 2023 Nov; 133(21):. PubMed ID: 37606995
[TBL] [Abstract][Full Text] [Related]
9. Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer.
Mäkinen N; Meyerson M
J Clin Invest; 2023 Nov; 133(21):. PubMed ID: 37909331
[TBL] [Abstract][Full Text] [Related]
10. Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
Necchi A; Ramlau R; Falcón González A; Chaudhry A; Todenhöfer T; Tahbaz R; Fontana E; Giannatempo P; Deville JL; Pouessel D; Yoon S; Powles T; Bernat M; Häckl M; Marszewska M; McKernan P; Saulay M; Scaleia F; Engelhardt M; Loriot Y; Siefker-Radtke A; De Santis M
JNCI Cancer Spectr; 2024 Apr; 8(3):. PubMed ID: 38627238
[TBL] [Abstract][Full Text] [Related]
11. Phase II Study of Erdafitinib in Patients With Tumors With
Gong J; Mita AC; Wei Z; Cheng HH; Mitchell EP; Wright JJ; Ivy SP; Wang V; Gray RC; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Alva AS; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2024 Apr; 8():e2300406. PubMed ID: 38603651
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: Phase II study protocol.
Fujimura T; Yoshino K; Nakamura M; Kato H; Ito T; Maekawa T; Fujisawa Y; Matsushita S; Amagai R; Yamazaki E; Takahashi M; Tamabuchi E; Hashimoto A; Kambayashi Y; Yamazaki N; Miyata T; Asano Y
Exp Dermatol; 2024 Jan; 33(1):e14976. PubMed ID: 37946551
[TBL] [Abstract][Full Text] [Related]
13. Oncogene alterations in non-small cell lung cancer with
Kitai H; Ebi H
Transl Lung Cancer Res; 2024 Mar; 13(3):684-688. PubMed ID: 38601453
[No Abstract] [Full Text] [Related]
14. First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors.
Koyama T; Shimizu T; Iwasa S; Fujiwara Y; Kondo S; Kitano S; Yonemori K; Shimomura A; Iizumi S; Sasaki T; Furuse J; Yamamoto N
Cancer Sci; 2020 Feb; 111(2):571-579. PubMed ID: 31797489
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Selpercatinib in
Wirth LJ; Sherman E; Robinson B; Solomon B; Kang H; Lorch J; Worden F; Brose M; Patel J; Leboulleux S; Godbert Y; Barlesi F; Morris JC; Owonikoko TK; Tan DSW; Gautschi O; Weiss J; de la Fouchardière C; Burkard ME; Laskin J; Taylor MH; Kroiss M; Medioni J; Goldman JW; Bauer TM; Levy B; Zhu VW; Lakhani N; Moreno V; Ebata K; Nguyen M; Heirich D; Zhu EY; Huang X; Yang L; Kherani J; Rothenberg SM; Drilon A; Subbiah V; Shah MH; Cabanillas ME
N Engl J Med; 2020 Aug; 383(9):825-835. PubMed ID: 32846061
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Selpercatinib in
Drilon A; Oxnard GR; Tan DSW; Loong HHF; Johnson M; Gainor J; McCoach CE; Gautschi O; Besse B; Cho BC; Peled N; Weiss J; Kim YJ; Ohe Y; Nishio M; Park K; Patel J; Seto T; Sakamoto T; Rosen E; Shah MH; Barlesi F; Cassier PA; Bazhenova L; De Braud F; Garralda E; Velcheti V; Satouchi M; Ohashi K; Pennell NA; Reckamp KL; Dy GK; Wolf J; Solomon B; Falchook G; Ebata K; Nguyen M; Nair B; Zhu EY; Yang L; Huang X; Olek E; Rothenberg SM; Goto K; Subbiah V
N Engl J Med; 2020 Aug; 383(9):813-824. PubMed ID: 32846060
[TBL] [Abstract][Full Text] [Related]
17. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Abou-Alfa GK; Sahai V; Hollebecque A; Vaccaro G; Melisi D; Al-Rajabi R; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Ji T; Lihou CF; Zhen H; Féliz L; Vogel A
Lancet Oncol; 2020 May; 21(5):671-684. PubMed ID: 32203698
[TBL] [Abstract][Full Text] [Related]
18. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
[TBL] [Abstract][Full Text] [Related]
19. Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors.
Facchinetti F; Hollebecque A; Bahleda R; Loriot Y; Olaussen KA; Massard C; Friboulet L
Clin Cancer Res; 2020 Feb; 26(4):764-774. PubMed ID: 31585937
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
